Acura Pharmaceuticals (ACUR)
Acura Pharmaceuticals Revenues
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ACUR Revenues Range, Past 5 Years
| Minimum | -1.527M | Dec 2009 |
| Maximum | 20.23M | Jun 2011 |
| Average | 4.803M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these ACUR related companies
ACUR News
New MFI stock Acura Pharma $ACUR. On screen due to one-time payment in Q2 last year - no revenue since then. Specialty drug dev.
about 16 days ago by MagicDiligence
about 16 days ago by MagicDiligence
Acura Pharmaceuticals to Host First Quarter 2012 Financial Results Conference Call on May 2, 2012
Apr 24, 5:30PM Marketwire
Apr 24, 5:30PM Marketwire
Acura Pharmaceuticals to Present at the Needham Healthcare Conference on April 3, 2012
Mar 21, 7:00AM Marketwire
Mar 21, 7:00AM Marketwire
RT @Tape_Reader WATCH $ACUR $ARAY $SCEI $TGB $SMSI $UTSI http://stks.co/2vF8
about 70 days ago by Ammeo
about 70 days ago by Ammeo
$ACUR forms bullish "Bottom Triangle" chart pattern. http://stks.co/2tRq
about 72 days ago by RecogniaEvents
about 72 days ago by RecogniaEvents
$ACUR forms bullish "Continuation Wedge" chart pattern. http://stks.co/2tRW
about 72 days ago by RecogniaEvents
about 72 days ago by RecogniaEvents
Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results
Mar 05, 4:05PM Marketwire
Mar 05, 4:05PM Marketwire
buying some $acur on the pullback like the news to prevent meth heads from making meth from cold medicine
about 86 days ago by missyaubaby
about 86 days ago by missyaubaby
Acura Pharma (ACUR) Reports Encouraging Data from Independent NEXAFED Tests
Mar 02, 6:31AM Street Insider
Mar 02, 6:31AM Street Insider
Acura Pharmaceuticals to Report Fourth Quarter and Fiscal Year 2011 Financial Results
Feb 23, 11:30AM Marketwire
Feb 23, 11:30AM Marketwire
RT @BioRunUp $ACUR Acura Gains as Oxycodone Pill to Deter Abuse Reaches Market: Chicago Mover http://stks.co/255I via Bloomberg $PFE
about 123 days ago by brittpierpoint
about 123 days ago by brittpierpoint
Shares of Acura $ACUR resume trading up 13% (last traded at $4.24)
about 124 days ago by Street_Insider
about 124 days ago by Street_Insider
Acura $ACUR advised by Pfizer $PFE Oxecta is commercially available, receives tiered royalties of 5-25% on net sales
about 124 days ago by Street_Insider
about 124 days ago by Street_Insider
Acura Pharmaceuticals Provides Update on Opioid Product Licensed to Pfizer
Jan 23, 4:11PM Marketwire
Jan 23, 4:11PM Marketwire
$ACUR halted pending news - insiders sold quite a bit of stock earlier this month, which doesn't always mean anything but...
about 125 days ago by newnormsurvivor
about 125 days ago by newnormsurvivor
$ACUR is a small pharma co that develops pain relief drugs. Its flagship medication is OXECTA, a pain relief in collab w $PFE...no pos
about 125 days ago by EXPstocktrader
about 125 days ago by EXPstocktrader
RT @Street_Insider Acura Pharmaceuticals $ACUR halted with news pending
about 125 days ago by ChiBullsTrader
about 125 days ago by ChiBullsTrader
Acura Pharmaceuticals to Present at the BioCentury NewsMakers in the Biotech Industry Conference
Oct 18, 12:00PM Marketwire
Oct 18, 12:00PM Marketwire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ACUR | 3.05 | +0.28 | +10.11% | 139.87M |
| ACU | 10.66 | +0.45 | +4.41% | 33.05M |
| ACTV | 13.88 | +0.08 | +0.58% | 802.54M |
| ACTS | 1.66 | +0.01 | +0.61% | 115.67M |
| ACTG | 35.13 | -0.14 | -0.40% | 1.744B |
| ACRX | 3.53 | +0.07 | +2.17% | 69.08M |
| ACPW | 0.7397 | -0.00 | -0.04% | 70.19M |
| ACET | 8.25 | +0.03 | +0.36% | 221.10M |
| ACE | 73.18 | -0.06 | -0.08% | 24.67B |
| ACCU | 22.92 | +0.00 | +0.00% |